Delaying the second COVID-19 vaccine dose: A medical expert answers key questions
The uncertainty is around how long the protective effect of the first dose will last without a second shot
COVID-19 vaccines are coming – how will we know they work and are safe?
The results of the Pfizer vaccine trial are highly promising. But the road to eradicating the coronavirus is likely to be long and difficult
Why other African countries need to guard against South Africa COVID-19 variant
WHO and African Centres for Disease Control to strengthen genomic surveillance capacities
Dummy’s guide to how trade rules affect access to COVID-19 vaccines
The WTO is considering whether to temporarily waive certain rules about TRIPS, to allow more countries access to vaccines, drugs needed to …
Effectiveness of COVID-19 vaccines against infection, severe disease declined with new variants; here's how
AstraZeneca vaccine provided least protection against infection, showed most rapid decline
WATCH: Will mixing COVID-19 vaccines be effective?
Some early studies have shown that combining vaccines produce a better immune response. But the efficacy of the vaccine combination is yet to be …
COVID-19 vaccines: How Pfizer and Moderna’s 95% effective mRNA shots work
Should we expect the pandemic to be over once a vaccine is available for public use? Not exactly. A vaccine will not be perfect, and it takes …
Moderna’s COVID vaccine reports 95% efficacy. It means we might have multiple successful vaccines
It opens the door to the possibility we might have many successful vaccines, and be able to tailor different vaccines to people with different needs
COVID-19: Pfizer, AstraZeneca efficacy significantly reduced against omicron, says UK health agency
Omicron is displaying growth advantage over delta and is poised to become dominant variant in UK
Covaxin effective against UK Strain: What does this mean in absence of efficacy data?
Being a whole-virus vaccine doesn’t give Bharat Biotech product any advantage at this stage, say experts
Lateral Thoughts: Waiting for bad news
Adverse reactions are part and parcel of vaccination. We can know about safety of COVID-19 vaccines being used in India only after people receive …
COVID-19 immunity: how long does it last?
In UK’s second wave, previously infected health workers were either completely protected from reinfection or were asymptomatic
COVID-19 vaccine: Oxford-AstraZeneca up to 90% effective in late stage trial
Adenovirus vaccine can be stored at 2-8°C; company to apply for emergency authorisation
COVID-19 Challenge 2021: How does the world overcome vaccine shortage
The pharmaceuticals industry must come together to ensure all adults are vaccinated against the novel coronavirus; …
COVID-19 in Africa: The pain of getting the jab
The COVAX Facility and the African Union are struggling to bring some relief to Africa which has been suffering from vaccine apartheid
What COVID-19 vaccine side effects might I expect?
In the vast majority of cases, any side effect you feel will be over within a few days, and there is no reason for concern
Cost of vaccination has risen 68 times in a decade, says report
Crisis looms as donor withdraws support to African countries; MSF urges GSK, Pfizer to slash vaccine price
Coronavirus vaccines: TRIPS waiver caught in WTO labyrinth
Little change in the position of countries opposing waiver of intellectual property rights; India-South Africa proposal being through hoops …
DCGI clears Bharat Biotech, SII COVID-19 vaccines but efficacy question unanswered
CDSCO official says BB vaccine to be used in public but to exclude people with COVID-19, other infections
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
Decision on emergency authorisation for SII, Bharat Biotech’s COVID-19 vaccines deferred
Both manufacturers have been asked for more data before a final decision can be reached
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …
The world needs pharmaceuticals from China and India to beat COVID-19
Chinese manufacturers make around 40% of all APIs used worldwide; China, India are the source of 75-80% of APIs imported to US
Big pharma’s dirty tricks
Drug giants from GSK, Abbott and Pfizer to Bayer have been fined for serious malpractices. They should be under close watch in India
Standing up to the US
India does not have to be apologetic about its patents law, which is fully compliant with WTO requirements on intellectual property protection
.jpg "Cost of vaccination has risen 68 times in a decade, says report")
.jpg "The natco-pfizer test")
.jpg "Standing up to the US")
